WO2001064751A3 - High potency recombinant antibodies and method for producing them - Google Patents
High potency recombinant antibodies and method for producing them Download PDFInfo
- Publication number
- WO2001064751A3 WO2001064751A3 PCT/US2001/006815 US0106815W WO0164751A3 WO 2001064751 A3 WO2001064751 A3 WO 2001064751A3 US 0106815 W US0106815 W US 0106815W WO 0164751 A3 WO0164751 A3 WO 0164751A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- neutralizing
- high potency
- disclosed
- producing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001240020A AU2001240020B9 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
AU4002001A AU4002001A (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
ES01914657T ES2390761T3 (en) | 2000-03-01 | 2001-03-01 | Recombinant high-potency antibodies and method for their production |
CA002401652A CA2401652A1 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
DK01914657.0T DK1259547T3 (en) | 2000-03-01 | 2001-03-01 | HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM |
EP01914657A EP1259547B1 (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
JP2001564244A JP2003525061A (en) | 2000-03-01 | 2001-03-01 | High potency recombinant antibody and method for producing the same |
AU2006203134A AU2006203134B2 (en) | 2000-01-27 | 2006-07-21 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
AU2007202040A AU2007202040B2 (en) | 2000-03-01 | 2007-05-08 | High potency recombinant antibodies and method for producing them |
AU2010202006A AU2010202006B2 (en) | 2000-01-27 | 2010-05-18 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
AU2010219289A AU2010219289B2 (en) | 2000-03-01 | 2010-09-03 | High potency recombinant antibodies and method for producing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18625200P | 2000-03-01 | 2000-03-01 | |
US60/186,252 | 2000-03-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001064751A2 WO2001064751A2 (en) | 2001-09-07 |
WO2001064751A3 true WO2001064751A3 (en) | 2001-12-20 |
Family
ID=22684221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/006815 WO2001064751A2 (en) | 2000-01-27 | 2001-03-01 | High potency recombinant antibodies and method for producing them |
Country Status (10)
Country | Link |
---|---|
US (2) | US7700735B2 (en) |
EP (3) | EP1259547B1 (en) |
JP (2) | JP2003525061A (en) |
AU (4) | AU2001240020B9 (en) |
CA (1) | CA2401652A1 (en) |
CY (1) | CY1113298T1 (en) |
DK (1) | DK1259547T3 (en) |
ES (1) | ES2390761T3 (en) |
PT (1) | PT1259547E (en) |
WO (1) | WO2001064751A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986686B2 (en) | 2002-06-14 | 2015-03-24 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US9283274B2 (en) | 2009-10-06 | 2016-03-15 | Medimmune Limited | RSV specific binding molecule |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1265928T3 (en) * | 2000-01-27 | 2010-11-15 | Medimmune Llc | RSV neutralizing antibodies with ultra high affinity |
AU2001240020B9 (en) * | 2000-03-01 | 2008-12-04 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
TWI327599B (en) * | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
PT1355919E (en) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
CA2466025A1 (en) * | 2001-11-02 | 2003-08-07 | Centocor, Inc. | Rsv proteins, antibodies, compositions, methods and uses |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
ATE444308T1 (en) * | 2002-02-13 | 2009-10-15 | Ludwig Inst Cancer Res | FUSION PROTEINS OF HUMANIZED G250 SPECIFIC ANTIBODIES AND USES THEREOF |
CA2485548A1 (en) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
WO2003094859A2 (en) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
TW200501985A (en) * | 2002-07-25 | 2005-01-16 | Medimmune Inc | Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies |
US7541033B2 (en) | 2003-01-24 | 2009-06-02 | Applied Molecular Evolution, Inc. | Humanized anti-IL-1β antibodies |
WO2004092343A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
EP1617864A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | Epha2 and non-neoplastic hyperproliferative cell disorders |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
EP1720908A2 (en) * | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
US20090202986A1 (en) * | 2004-10-22 | 2009-08-13 | Huse William D | Methods of optimizing antibody variable region binding affinity |
EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
BRPI0708636A2 (en) * | 2006-03-06 | 2011-06-07 | Symphogen As | recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
WO2008070042A2 (en) * | 2006-12-04 | 2008-06-12 | Medimmune, Inc. | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
MX2009009226A (en) * | 2007-03-06 | 2009-10-28 | Symphogen As | Recombinant antibodies for treatment of respiratory syncytial virus infections. |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
JP2010531878A (en) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ,インコーポレーテッド | Complex of IL-15 and IL-15Rα and use thereof |
EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
WO2010068722A1 (en) | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2011020024A2 (en) | 2009-08-13 | 2011-02-17 | The Johns Hopkins University | Methods of modulating immune function |
WO2011062560A1 (en) * | 2009-11-19 | 2011-05-26 | National University Of Singapore | Method for producing t cell receptor-like monoclonal antibodies and uses thereof |
JP5808349B2 (en) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | Biomarkers for theranosis |
KR20130043104A (en) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | Circulating biomarkers for disease |
JP5891298B2 (en) | 2011-05-04 | 2016-03-22 | オメロス コーポレーション | Composition for inhibiting MASP-2-dependent complement activation |
EA033109B1 (en) | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Methods of inhibiting, preventing or treating diarrhea and/or maintaining appropriate electrolyty and fluid levels in the colon of a subject having a condition associated with diarrhea using an anti-cgrp antibody or an anti-cgrp antibody fragment |
JP6374789B2 (en) | 2011-05-20 | 2018-08-15 | アルダーバイオ・ホールディングズ・エルエルシー | Use of anti-CGRP antibodies and antibody fragments that prevent or inhibit photophobia or photoaversion in subjects in need thereof, particularly migraine patients |
SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
AU2017345759A1 (en) | 2016-10-21 | 2019-05-23 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
JP2020503843A (en) | 2016-10-21 | 2020-02-06 | アディマブ, エルエルシー | Anti-respiratory syncytial virus antibodies and methods for their production and use |
US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
MX2021008267A (en) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005229A1 (en) * | 1994-08-15 | 1996-02-22 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
EP0699756A1 (en) * | 1994-08-04 | 1996-03-06 | Bristol-Myers Squibb Company | Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas |
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
WO1998033919A2 (en) * | 1997-01-30 | 1998-08-06 | Ixsys, Incorporated | Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0043272B1 (en) | 1980-07-01 | 1984-06-13 | National Research Development Corporation | Production of viral antigens |
JPS58500366A (en) | 1981-03-06 | 1983-03-10 | セルテツク リミテツド | single clone antibody |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
US5340926A (en) | 1983-03-25 | 1994-08-23 | Celltech, Limited | Process for the recovery of recombinantly produced protein from insoluble aggregate |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US5332805A (en) | 1984-02-03 | 1994-07-26 | Celltech Limited | Process for the recovery of recombinantly produced chymosin from insoluble aggregate |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
FR2590674B1 (en) | 1985-11-25 | 1989-03-03 | Inst Nat Sante Rech Med | NEW DIAGNOSTIC REAGENTS |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4717766A (en) | 1986-01-27 | 1988-01-05 | Miles Laboratories, Inc. | Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin |
US4659563A (en) | 1986-01-27 | 1987-04-21 | Miles Laboratories, Inc. | High titer anti-respiratory syncytial virus intravenous immune globulin |
US5271927A (en) | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
US5468606A (en) | 1989-09-18 | 1995-11-21 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4800078A (en) | 1987-05-28 | 1989-01-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
GB8719041D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
US4916893A (en) * | 1987-09-02 | 1990-04-17 | Sundstrand Corporation | Multipurpose auxiliary power unit |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223254A (en) | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
DE3878468T2 (en) | 1987-12-23 | 1993-06-09 | Upjohn Co | CHIMARENE GLYCOPROTEINS, CONTAINING IMMUNOGENIC SEGMENTS OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS. |
WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
US5183657A (en) | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
JPH01268646A (en) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | Antitumor agent |
US5137804A (en) | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5354554A (en) | 1989-02-10 | 1994-10-11 | Celltech Limited | Crosslinked antibodies and processes for their preparation |
US6093872A (en) | 1989-05-05 | 2000-07-25 | Systemix, Inc. | Extended human hematopoiesis in a heterologous host |
FR2650598B1 (en) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION |
US5332567A (en) | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5518725A (en) | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
JP2571874B2 (en) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Protein microsphere composition |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5279935A (en) | 1990-03-01 | 1994-01-18 | Becton, Dickinson And Company | Method of immunossay including deactivation of endogenous alkaline phosphatase |
AU637914B2 (en) | 1990-05-03 | 1993-06-10 | Systemix, Inc. | Human lymphoid tissue in an immunocompromised host |
US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
DK1471142T3 (en) * | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
ES2113428T3 (en) | 1991-04-22 | 1998-05-01 | Massachusetts Health Res | SCREENING PROCESS OF PLASMA SAMPLES TO DETERMINE ANTIBODY TITLES EFFECTIVE AGAINST RESPIRATORY VIRUSES. |
CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
CA2044940A1 (en) | 1991-06-10 | 1992-12-11 | Inder M. Verma | Transdominant negative proto-oncogene |
US5240694A (en) | 1991-09-23 | 1993-08-31 | University Of Virginia | Combined antiviral and antimediator treatment of common colds |
US5418136A (en) | 1991-10-01 | 1995-05-23 | Biostar, Inc. | Devices for detection of an analyte based upon light interference |
JP3253300B2 (en) * | 1991-11-15 | 2002-02-04 | コーネル リサーチ ファウンデイション インコーポレイテッド | Indirect immunoassay for dioxin analogs |
US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
ES2191016T3 (en) | 1992-09-16 | 2003-09-01 | Scripps Research Inst | HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES FOR THE SYNCTIAL RESPIRATORY VIRUS. |
US6685942B1 (en) | 1993-12-10 | 2004-02-03 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | Methods and compositions for the direct concentrated delivery of passive immunity. |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5424189A (en) | 1993-03-05 | 1995-06-13 | Kansas State University Research Foundation | Bovine respiratory syncytial virus detection and primers |
WO1995004081A1 (en) | 1993-07-30 | 1995-02-09 | Oravax, Inc. | MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS |
US5506209A (en) | 1994-05-26 | 1996-04-09 | Abbott Laboratories | Product for inhibition of infection of mammalian cells by respiratory syncytial virus |
US5538952A (en) | 1994-05-26 | 1996-07-23 | Abbott Laboratories | Inhibition of infection of mammalian cells by respiratory syncytial virus |
US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
DE69609188T2 (en) | 1995-09-18 | 2000-12-21 | Intracel Corp | NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS |
DK0885002T3 (en) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materials and methods for enhancing cellular internalization |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
FR2758331B1 (en) | 1997-01-14 | 1999-03-05 | Univ Bourgogne | NEW MEANS FOR DIAGNOSIS, PREVENTION AND TREATMENT FOR CONTAMINATION OR INFECTIONS WITH MUCOUS TROPISM VIRUSES |
US6117980A (en) | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK1265928T3 (en) | 2000-01-27 | 2010-11-15 | Medimmune Llc | RSV neutralizing antibodies with ultra high affinity |
AU2001240020B9 (en) | 2000-03-01 | 2008-12-04 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
WO2001059142A1 (en) | 2000-02-09 | 2001-08-16 | Medimmune, Inc. | Antibody gene therapy with adeno-associated viral vectors |
US6565849B2 (en) | 2000-03-02 | 2003-05-20 | Medimmune, Inc. | Methods of enhancing activity of vaccines and vaccine compositions |
WO2001079299A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
ATE300713T1 (en) | 2000-05-03 | 2005-08-15 | Ipv Inheidener Produktions Und | THERMAL CONTAINER |
WO2001082965A1 (en) | 2000-05-03 | 2001-11-08 | Medimmune, Inc. | Combination therapy of respiratory diseases using antibodies |
JP2003531867A (en) | 2000-05-03 | 2003-10-28 | メディミューン,インコーポレイテッド | Combination therapy of respiratory diseases using antibodies and anti-inflammatory drugs |
US20020018780A1 (en) | 2000-05-25 | 2002-02-14 | Scott Koenig | Epitope-based vaccine for respiratory syncytial virus F-protein |
JP5490972B2 (en) | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | Protein injection formulation |
US6565888B1 (en) | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
TWI327599B (en) | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP1812068A4 (en) | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
-
2001
- 2001-03-01 AU AU2001240020A patent/AU2001240020B9/en not_active Ceased
- 2001-03-01 WO PCT/US2001/006815 patent/WO2001064751A2/en active Application Filing
- 2001-03-01 PT PT01914657T patent/PT1259547E/en unknown
- 2001-03-01 DK DK01914657.0T patent/DK1259547T3/en active
- 2001-03-01 JP JP2001564244A patent/JP2003525061A/en active Pending
- 2001-03-01 EP EP01914657A patent/EP1259547B1/en not_active Expired - Lifetime
- 2001-03-01 AU AU4002001A patent/AU4002001A/en active Pending
- 2001-03-01 EP EP10010677A patent/EP2341074A1/en not_active Withdrawn
- 2001-03-01 ES ES01914657T patent/ES2390761T3/en not_active Expired - Lifetime
- 2001-03-01 CA CA002401652A patent/CA2401652A1/en not_active Abandoned
- 2001-03-01 US US09/796,848 patent/US7700735B2/en not_active Expired - Fee Related
- 2001-03-01 EP EP10010678A patent/EP2341075A1/en not_active Withdrawn
-
2007
- 2007-05-08 AU AU2007202040A patent/AU2007202040B2/en not_active Ceased
-
2010
- 2010-02-09 JP JP2010026290A patent/JP2010162025A/en active Pending
- 2010-02-17 US US12/707,527 patent/US8153133B2/en not_active Expired - Fee Related
- 2010-09-03 AU AU2010219289A patent/AU2010219289B2/en not_active Ceased
-
2012
- 2012-10-05 CY CY20121100934T patent/CY1113298T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
EP0699756A1 (en) * | 1994-08-04 | 1996-03-06 | Bristol-Myers Squibb Company | Novel mutant BR96 antibodies and functional equivalents reactive with human carcinomas |
WO1996005229A1 (en) * | 1994-08-15 | 1996-02-22 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
WO1998033919A2 (en) * | 1997-01-30 | 1998-08-06 | Ixsys, Incorporated | Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use |
Non-Patent Citations (3)
Title |
---|
HEFTA L J F ET AL: "Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs", IMMUNOTECHNOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS BV, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 49 - 57, XP004127386, ISSN: 1380-2933 * |
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY,LONDON,GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP000978702, ISSN: 0022-2836 * |
YANG W -P ET AL: "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 254, 1995, pages 392 - 403, XP000199739, ISSN: 0022-2836 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986686B2 (en) | 2002-06-14 | 2015-03-24 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US9272032B2 (en) | 2002-06-14 | 2016-03-01 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US9283274B2 (en) | 2009-10-06 | 2016-03-15 | Medimmune Limited | RSV specific binding molecule |
Also Published As
Publication number | Publication date |
---|---|
AU2007202040B2 (en) | 2010-06-10 |
US8153133B2 (en) | 2012-04-10 |
US7700735B2 (en) | 2010-04-20 |
AU2007202040A1 (en) | 2007-05-24 |
AU2001240020B9 (en) | 2008-12-04 |
PT1259547E (en) | 2012-10-15 |
AU4002001A (en) | 2001-09-12 |
CY1113298T1 (en) | 2016-04-13 |
AU2010219289A1 (en) | 2010-09-30 |
JP2010162025A (en) | 2010-07-29 |
DK1259547T3 (en) | 2012-10-15 |
JP2003525061A (en) | 2003-08-26 |
WO2001064751A2 (en) | 2001-09-07 |
AU2010219289B2 (en) | 2012-05-10 |
CA2401652A1 (en) | 2001-09-07 |
EP1259547B1 (en) | 2012-07-11 |
AU2001240020B2 (en) | 2007-02-08 |
ES2390761T3 (en) | 2012-11-16 |
EP2341075A1 (en) | 2011-07-06 |
EP1259547A2 (en) | 2002-11-27 |
EP2341074A1 (en) | 2011-07-06 |
US20020098189A1 (en) | 2002-07-25 |
US20100239574A1 (en) | 2010-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001064751A3 (en) | High potency recombinant antibodies and method for producing them | |
ATE402192T1 (en) | ANTI-CCR4 ANTIBODIES AND FRAGMENTS THEREOF | |
PL343245A1 (en) | Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses | |
WO2000076540A3 (en) | Streptococcus pneumoniae proteins and vaccines | |
IL128014A (en) | Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine | |
WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
WO2002024887A3 (en) | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen | |
WO2005061537A3 (en) | Squamous cell carcinoma antigens and use thereof | |
WO2002044366A3 (en) | Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 | |
HU9300349D0 (en) | Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them | |
WO2001075015A3 (en) | A novel polypeptide, fat24 and the polynucleotide encoding the polypeptide | |
WO2001036979A3 (en) | Placental human neurokinin b precursor | |
WO2001075039A3 (en) | A novel polypeptide, human rna helicase 10 and the polynucleotide encoding the polypeptide | |
WO2001088084A3 (en) | A novel polypeptide, a superoxide dismutase 11 and the polynucleotide encoding the polypeptide | |
WO2001075061A3 (en) | A novel polypeptide, cdv-1-42 and the polynucleotide encoding the polypeptide | |
WO2001083675A3 (en) | A novel polypeptide, a atp-dependent human hydrolase serine 10.2 and the polynucleotide encoding the polypeptide | |
WO2001075021A3 (en) | A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide | |
WO2001075006A3 (en) | A novel poypeptide, light chain of protein lattice 37 and the polynucleotide encoding the polypeptide | |
WO2001075036A3 (en) | A novel polypeptide, human immunophiline 14 and the polynucleotide encoding the polypeptide | |
WO2001075051A3 (en) | A novel polypeptide, a human stroma antigen 3 protein 17 and the polynucleotide encoding the polypeptide | |
WO2001075016A3 (en) | A novel polypeptide, a human tyrosinase 16, and the polynucleotide encoding the polypeptide | |
WO2001075042A3 (en) | A novel polypeptide, atp-dependent human hydrolase serine 9 and the polynucleotide encoding the polypeptide | |
WO2002000831A3 (en) | A novel polypeptide, a bromine group domain 12 and the polynucleotide encoding the polypeptide | |
WO2001075056A3 (en) | A novel polypeptide, human light-chain clathrine 20 and the polynucleotide encoding the polypeptide | |
WO2001074128A3 (en) | A novel polypeptide, microtubulin 11 and the polynucleotide encoding the polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001240020 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001914657 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401652 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564244 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001914657 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |